GRAIL, Inc.
Ofman Joshua J. (Chief Executive Officer) sold 20,000 shares of GRAIL, Inc. (GRAL) at an average of $136.85 ($133.12–$138.79, $2.74M total) across 6 trades on 2026-10-15 under a Rule 10b5-1 trading plan.
TD Cowen raised its price target for Grail (NASDAQ:GRAL) to $180 from $88, citing increased FDA approval prospects and CMS reimbursement confidence. The stock has surged 186% in six months. Analysts highlight high valuation multiples and regulatory developments as key factors. Grail develops early cancer detection tests.
Grail (GRAL) stock rose 80% in a month after FDA panel backed its Galleri test, but insurers' pricing decisions remain a key risk factor. The test's adoption depends on cost-benefit analysis, including false positives and pricing at $949.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning GRAL (GRAIL, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent GRAL coverage spans financial news, insider activity and regulation.
In the last 30 days, GRAL insiders filed 19 SEC Form 4 transactions — no purchases and 19 sales ($13.7M). The most active reporter was Ofman Joshua J., Chief Executive Officer, with 14 filings. 89% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may signal reduced confidence or portfolio rebalancing, potentially pressuring the stock.
Analyst upgrade may support modest upside as investors price in higher valuation.
Positive panel vote suggests imminent FDA approval, likely driving further upside.
Grail faces pressure due to high cash burn and negative margins, suggesting limited upside.
The insider sale may weigh on the stock as investors price in potential concerns.
AlphAI scores every news story that mentions GRAL with an AI model for sentiment and relevance, and aggregates insider trades from GRAIL, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ofman Joshua J. (Chief Executive Officer) sold 20,000 shares of GRAIL, Inc. (GRAL) at an average of $136.85 ($133.12–$138.79, $2.74M total) across 6 trades on 2026-10-15 under a Rule 10b5-1 trading plan.
1 min readTD Cowen raised its price target for Grail (NASDAQ:GRAL) to $180 from $88, citing increased FDA approval prospects and CMS reimbursement confidence. The stock has surged 186% in six months. Analysts highlight high valuation multiples and regulatory developments as key factors. Grail develops early cancer detection tests.
2 min readGrail (GRAL) stock rose 80% in a month after FDA panel backed its Galleri test, but insurers' pricing decisions remain a key risk factor. The test's adoption depends on cost-benefit analysis, including false positives and pricing at $949.
2 min readGRAIL (GRAL) and Guardant Health (GH) both sell cancer-detection blood tests. GH has higher revenue ($1.18B vs $165M), growth (44.30% vs 25.70%), and market cap ($22.59B vs $5.94B), but GRAL has more cash ($861.61M vs $1.05B) and less debt ($91.31M vs $1.70B). Both lack earnings, with GRAL at $133 and GH at $168 as of October 7.
2 min readGRAIL CFO Aaron Freidin sold 23,619 shares for $3.46m at $146.39 each to cover taxes. He holds 225,364 shares. GRAL stock is down from the sale price but up 170% in six months. Analysts have mixed views on its valuation and FDA test approval prospects. Price targets range from $80 to $150.
1 min readGRAIL's Chief Growth Officer Andrew Partridge sold 7,873 shares worth $1.15m at $146.39 each on Oct 5, 2026, to cover taxes. He now holds 155,865 shares. The stock is down from the sale price but up 170% in six months. Analysts have mixed views on its valuation and price targets post-FDA panel approval of its Galleri test.
1 min readPartridge Andrew John (Chief Growth Officer) sold 7,873 shares of GRAIL, Inc. (GRAL) at $146.39 ($1.15M total) on 2026-10-05.
1 min readFreidin Aaron (Chief Financial Officer) sold 23,619 shares of GRAIL, Inc. (GRAL) at $146.39 ($3.46M total) on 2026-10-05.
1 min readGRAIL (GRAL) presented new data from its NHS-Galleri and PATHFINDER 2 studies, focusing on its Galleri multi-cancer early detection blood test. The stock fell 10.9% to $137.28 but has seen a 30-day return of 70.87% and a 1-year return of 118.53%. Analysts suggest the stock may be 41% overvalued at $97.40, citing strong momentum but also significant risks.
2 min readJim Cramer commented on three stocks: CVS Health (CVS) is 'insanely cheap' at $86.68, with strong fundamentals and raised guidance. ON Semiconductor (ON) is catching up post-Synaptics deal, trading at $84.00. Grail (GRAL), at $5.7B market cap, is too expensive at 34x sales, according to Cramer.
2 min read
